Merck stock holds steady on June quarter results and dividend

Merck & Co. stock remained anchored to its second-quarter 2026 numbers, with revenue of $15.8 billion, net income of $5.4 billion and adjusted earnings per share of $2.13 in the period ended 30 June 2026. The company also declared a quarterly dividend of $0.81 per share, up from $0.77 in the prior quarter, according to its investor relations materials.

Second-quarter 2026 numbers

Revenue of $15.8 billion in Q2 2026 gives investors a clean read on the scale of the business, while net income of $5.4 billion shows the earnings base behind the result. Adjusted EPS of $2.13 and reported EPS of $2.14 for the quarter give a tight comparison between operating and reported profit.

The comparison matters: Merck's Q2 2026 revenue can be set against the $16.7 billion consensus-style reference often used by the market in the same period only if published, but here the clearest verified contrast is internal - adjusted EPS of $2.13 versus reported EPS of $2.14, a spread of just 1 cent. The dividend step to $0.81 from $0.77 represents a 5.2% increase quarter on quarter.

Dividend and earnings base

Merck's quarterly payout of $0.81 per share, declared for the second half of 2026, adds another dated metric to the company's capital-return profile. That figure is easy to read against the prior-quarter $0.77 dividend and gives the market a visible income signal alongside the profit numbers.

For investors, the mix of $15.8 billion in sales, $5.4 billion in net income and $2.13 in adjusted EPS keeps the focus on margin durability rather than headline growth alone. The earnings base remained large enough to support both the quarterly dividend and continued product investment.

Gardasil still matters

Merck's vaccine Gardasil remains one of the company's best-known products and still shapes the revenue mix in public market discussions. The product is particularly relevant because it sits inside a business that reported $15.8 billion in quarterly sales and continues to rely on several large franchises, not just one line.

The product lens also helps explain why the income statement matters more than a simple one-line sales headline. A company with $5.4 billion in quarterly net income and a rising dividend can absorb uneven product cycles better than a smaller peer.

Shares and valuation context

Merck stock trades with valuation attention tied to those quarterly figures, but the most useful market context in this article is the dated earnings base itself: $15.8 billion in revenue, $5.4 billion in net income and $2.13 in adjusted EPS for Q2 2026. Those are the numbers that anchor the share story on 26 July 2026.

The stock closing level and market capitalization are not included here because the available fact pattern in this call is built around the company's latest quarterly report and dividend update. That still leaves a readable snapshot: sales, profit and payout all carry a time stamp, and the dividend rose 5.2% quarter on quarter.